Research map: Combination AURKA and WEE1 inhibition exhibits efficacy in EGFR or pan-ERBB inhibitor resistant head and neck squamous cell carcinoma

Back to the article

Papers in this map

  1. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck · James A. Bonner · 2006 · 5136 citations · Cited by this paper
  2. Chemotherapy-Induced Neutropenia in Palestinian Patients with Solid Malignancies: Patient Characteristics, Severity Risk Factors, and Management Patterns · 2026 · Related
  3. Head and neck squamous cell carcinoma · Daniel E. Johnson · 2020 · 4229 citations · Cited by this paper
  4. Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study · 2026 · Related
  5. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study · Barbara Ann Burtness · 2019 · 3349 citations · Cited by this paper
  6. Acquisition of Resistance to RAS Inhibition Is Associated with the Upregulation of Macropinocytosis through Both PI3K-Dependent and -Independent Signaling · 2026 · Related
  7. Cancer statistics, 2025 · Rebecca L. Siegel · 2025 · 2992 citations · Cited by this paper
  8. Transcriptionally Informed Nucleosome Profiling of Circulating Cell-Free DNA Predicts Breast Cancer Recurrence · 2026 · Related
  9. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 · Martin Scheffner · 1993 · 2415 citations · Cited by this paper
  10. Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway · 2026 · Related
  11. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction · Ji Luo · 2009 · 1796 citations · Cited by this paper
  12. Development of Glypican 3–Targeting Antibody–Drug Conjugates for Hepatocellular Carcinoma Therapy · 2026 · Related
  13. An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance · Lauren A. Byers · 2012 · 1139 citations · Cited by this paper
  14. Natural Autoantibodies Negatively Correlate with Hepatocellular Carcinoma Incidence in Cirrhosis · 2026 · Related
  15. EGFR Mutations and Lung Cancer · Gilda da Cunha Santos · 2011 · 991 citations · Cited by this paper
  16. BRAF Inhibition–Associated Nuclear Remodeling is Linked to Cancer-Associated Fibroblast Activation · 2026 · Related
  17. Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study · Barbara Ann Burtness · 2005 · 883 citations · Cited by this paper
  18. Tissue Context Shapes Distinct Premalignant Outcomes in an HPV16 E6/E7-Mutant Pik3ca Transgenic Mouse Model · 2026 · Related
  19. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples · Aleksandr Ianevski · 2022 · 815 citations · Cited by this paper
  20. Glioblastoma subtypes exhibit distinct migration mechanics and immune responses · 2026 · Related
  21. Structural Basis of Aurora-A Activation by TPX2 at the Mitotic Spindle · Richard Bayliss · 2003 · 660 citations · Cited by this paper
  22. Aurora A kinase (AURKA) in normal and pathological cell division · Anna S. Nikonova · 2012 · 467 citations · Cited by this paper
  23. The present and future of the Cancer Dependency Map · Rand Arafeh · 2024 · 436 citations · Cited by this paper
  24. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial · Jean‐Pascal Machiels · 2015 · 395 citations · Cited by this paper
  25. Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays · Mark G Manfredi · 2011 · 309 citations · Cited by this paper
  26. The cellular 107K protein that binds to adenovirus E1A also associates with the large T antigens of SV40 and JC virus · Nicholas J. Dyson · 1989 · 308 citations · Cited by this paper
  27. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer · Khyati Niral Shah · 2018 · 296 citations · Cited by this paper
  28. A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer · Daniel Dauch · 2016 · 275 citations · Cited by this paper
  29. A Convergence-Based Framework for Cancer Drug Resistance · David Joseph Konieczkowski · 2018 · 267 citations · Cited by this paper
  30. EGFR-targeted therapies in the post-genomic era · Mary Jue Xu · 2017 · 249 citations · Cited by this paper
  31. The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome · Elena N. Pugacheva · 2005 · 240 citations · Cited by this paper
  32. Cancer drug resistance induced by EMT: novel therapeutic strategies · Javier De Las Rivas · 2021 · 238 citations · Cited by this paper
  33. Prevalence of Human Papillomavirus in Oropharyngeal Cancer · Andrew P. Stein · 2015 · 236 citations · Cited by this paper
  34. Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas · Jonathan W. Friedberg · 2013 · 212 citations · Cited by this paper
  35. Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial · Renato G Martins · 2013 · 206 citations · Cited by this paper
  36. Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors · Mark W. Richards · 2016 · 193 citations · Cited by this paper
  37. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck · Tanguy Y. Seiwert · 2014 · 183 citations · Cited by this paper
  38. TGF-β, EMT, and resistance to anti-cancer treatment · Xuecong Wang · 2023 · 174 citations · Cited by this paper
  39. Drugging the addict: non‐oncogene addiction as a target for cancer therapy · Remco Nagel · 2016 · 163 citations · Cited by this paper

Source: OpenAlex (CC0)